Dr. rer. nat. Gianmaria Liccardi

Academic education

2006 – 2011 PhD in Molecular Oncology, University College London (UCL), London, UK

2003 – 2004 MSc Molecular Medicine, Imperial College, London, UK

2000 – 2003 BSc Molecular Genetics in Biotechnology, University of Sussex, Brighton, UK

Scientific degrees

2011 PhD, in Molecular Oncology, University College London, UK: EGFR modulation of chemotherapy and radiotherapy

2004 Master with distinction in Molecular Medicine Identification of the Yaa mutation in BXSB Lupus erythematosus Imperial College London, UK

2003 BSc (Hons) first class, University of Sussex Characterization of the P27kip1 phosphorylation in the regulation of RB

Scientific career

2022 - present Honorary Lecturer in Cell & Developmental Biology, University College, London, UK

2022-present Lecturer MSSO, University of Cologne, Germany

03/2021 - present Junior Group Leader, Center for Biochemistry, University of Cologne, Cologne,

2020 - 2021 Senior Post-doctoral Fellow, CECAD Research Centre, University of Cologne

2012 - 2019 Post-doctoral Fellow, The Institute of Cancer Research, London, UK

2018 - present Editorial board member, Editor of Cell Death Disease, Nature Publishing group

2018 - present Lecturer for MSc Oncology, The Institute of Cancer Research, London, UK

2011 - 2012 Post-doctoral Fellow, UCL Cancer Institute, UCL, London, UK

2006 - 2011 PhD student, UCL Cancer Institute, UCL, London, UK

2010-present Lecturer, Faculty of Life Science, UCL, London, UK

2010 - 2012 Lecturer for MSc Cancer, UCL Cancer Institute, UCL, London, UK

2006 - 2010 Teaching Assistant, Faculty of Life Science, UCL, London, UK

2005 - 2006 Research Assistant, Imperial College, London, UK

2003 - 2004 MSc student, Imperial College, London, UK

Contact Information

Dr. rer. nat. Gianmaria Liccardi SFB1399
Dr. rer. nat. Gianmaria Liccardi

Junior Research Group Leader Oncology

University of Cologne

Center of Biochemistry

Curriculum Vitae (CV)

10 most relevant publications

  • Montinaro, A., I. Areso Zubiaur, J. Saggau, A. L. Kretz, R. M. M. Ferreira, O. Hassan, E. Kitzig, I. Muller, M. A. El-Bahrawy, S. von Karstedt, D. Kulms, G. Liccardi, J. Lemke and H. Walczak (2021). Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. Cell Death Differ. Publication obtained during my appointment in Cologne
  • Garcia, L. R., T. Tenev, R. Newman, R. O. Haich, G. Liccardi, S. W. John, A. Annibaldi, L. Yu, M. Pardo, S. N. Young, C. Fitzgibbon, W. Fernando, N. Guppy, H. Kim, L. Y. Liang, I. S. Lucet, A. Kueh, I. Roxanis, P. Gazinska, M. Sims, T. Smyth, G. Ward, J. Bertin, A. M. Beal, B. Geddes, J. S. Choudhary, J. M. Murphy, K. Aurelia Ball, J. W. Upton and P. Meier (2021). Ubiquitylation of MLKL at lysine 219 positively regulates necroptosis-induced tissue injury and pathogen clearance. Nat Commun 12(1): 3364.
  • Smith, H. G., K. Jamal, J. H. Dayal, T. Tenev, J. Kyula-Currie, N. Guppy, P. Gazinska, V. Roulstone, G. Liccardi, E. Davies, I. Roxanis, A. A. Melcher, A. J. Hayes, G. J. Inman, K. J. Harrington and P. Meier (2020). RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma. EMBO Mol Med 12(6): e10979.
  • Ruiz, E. J., M. E. Diefenbacher, J. K. Nelson, R. Sancho, F. Pucci, A. Chakraborty, P. Moreno, A. Annibaldi, G. Liccardi, V. Encheva, R. Mitter, M. Rosenfeldt, A. P. Snijders, P. Meier, M. A. Calzado and A. Behrens (2019). LUBAC determines chemotherapy resistance in squamous cell lung cancer. J Exp Med 216(2): 450-465.
  • Liccardi, G., L. Ramos Garcia, T. Tenev, A. Annibaldi, A. J. Legrand, D. Robertson, R. Feltham, H. Anderton, M. Darding, N. Peltzer, M. Dannappel, H. Schunke, L. L. Fava, M. D. Haschka, T. Glatter, A. Nesvizhskii, A. Schmidt, P. A. Harris, J. Bertin, P. J. Gough, A. Villunger, J. Silke, M. Pasparakis, K. Bianchi and P. Meier (2019). RIPK1 and Caspase-8 Ensure Chromosome Stability Independently of Their Role in Cell Death and Inflammation. Mol Cell 73(3): 413-428 e417.
  • Anderton, H., E. Bandala-Sanchez, D. S. Simpson, J. A. Rickard, A. P. Ng, L. Di Rago, C. Hall, J. E. Vince, J. Silke, G. Liccardi* and R. Feltham* (2019). RIPK1 prevents TRADD-driven, but TNFR1 independent, apoptosis during development. Cell Death Differ 26(5): 877-889.
  • Annibaldi, A., S. Wicky John, T. Vanden Berghe, K. N. Swatek, J. Ruan, G. Liccardi, K. Bianchi, P. R. Elliott, S. M. Choi, S. Van Coillie, J. Bertin, H. Wu, D. Komander, P. Vandenabeele, J. Silke and P. Meier (2018). Ubiquitin-Mediated Regulation of RIPK1 Kinase Activity Independent of IKK and MK2. Mol Cell 69(4): 566-580 e565.
  • Barry, R., S. W. John, G. Liccardi, T. Tenev, I. Jaco, C. H. Chen, J. Choi, P. Kasperkiewicz, T. Fernandes-Alnemri, E. Alnemri, M. Drag, Y. Chen, and P. Meier. 2018. SUMO-mediated regulation of NLRP3 modulates inflammasome activity. Nat Commun 9 (1):3001.

  • Jaco, I., A. Annibaldi, N. Lalaoui, R. Wilson, T. Tenev, L. Laurien, C. Kim, K. Jamal, S. Wicky John, G. Liccardi, D.Chau, J. M. Murphy, G. Brumatti, R. Feltham, M. Pasparakis, J. Silkeand P. Meier (2017). MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death. MolCell 66(5): 698-710 e695.

  • Braso-Maristany, F., S. Filosto, S. Catchpole, R. Marlow, J. Quist, E. Francesch-Domenech, D. A. Plumb, L. Zakka, P. Gazinska, G. Liccardi, P. Meier, A. Gris-Oliver, M. C. Cheang, A. Perdrix-Rosell, M. Shafat, E. Noel, N. Patel, K. McEachern, M. Scaltriti, P. Castel, F. Noor, R. Buus, S. Mathew, J. Watkins, V. Serra, P. Marra, A. Grigoriadis and A. N. Tutt (2016). PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med 22(11): 1303-1313